The Jackson Laboratory provides the most widely published and cutting-edge models for oncology research and offers a comprehensive suite of solutions for your oncology research needs.
Over 400 patient-derived xenograft (PDX) tumors are available for engrafting into immunocompromised NSG™ mice for shipment to your facility or use in JAX-directed preclinical efficacy studies.
A robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells.
Your research shouldn't wait,
JAX is here when you need us
This webinar highlights recent advances and future directions using xenografted humanized NSG™ mice with functional human immune cells, to evaluate cancer immunotherapies.
A research team at JAX is boosting the speed and accuracy of tumor sample image analysis, for multiple cancer types,...
Using sophisticated labeling methods, a team led by Professor Karolina Palucka, M.D., Ph.D., and Jan Martinek, Ph.D.,...
Join us for our next Humanized Mice Journal Club where we will discuss experimental immune response to human melanomas with...
Join us as we discuss a new onco-hu model of ER+, ESR1-mutant, endocrine-resistant metastatic breast cancer.
Join our live discussion on preclinical efficacy and safety testing for novel antibody-based therapeutics.
Resource to find local cancer genetics experts.
PDX LIVE TUMOR INTEREST FORM - ACADEMIC PRICING
PDX LIVE TUMOR INTEREST FORM
Cutting Edge Bioinformatics for Preclinical Oncology. Dig deeper to understand tumor response or resistance to your...
Online Resources for Cancer Research
There are hundreds of JAX® Mice strains available for cancer research and drug efficacy testing. The table below summarizes...
Onco-Hu® models are a robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells to...
The Jackson Laboratory is proud to announce the 2022 recipients of the JAX Postdoctoral Scholar award. Eric Bogenschutz, Jayna Mistry, and...